natgillin/translations-raw huggingface dataset:
Caution is needed when administrating this vaccine to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients listed in section 6.1 and to eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB).
Pri uporabi tega cepiva pri osebah z znano preobčutljivostjo (razen anafilaktičnih reakcij) na učinkovino, katero koli pomožno snov, navedeno v poglavju 6.1, in na jajca, piščančje beljakovine,
Particular attention should be given to subjects suffering from epilepsy and the physician should inform the subjects (or parents) about the possibility to experience convulsion.
Zdravnik mora te osebe (ali starše) obvestiti o možnosti konvulzij (glejte poglavje 4.8).
Study V87P1 21 days after 2nd dose N=70
Študija V87P1 21. dan po 2. odmerku n = 70
Milky-white liquid.
Guillain-Barréjev sindrom.
Study V87P13 21 days after 2nd dose N=128
Študija V87P13 21. dan po 2. odmerku n = 128
OTHER
OKOLIŠČINAH
Study V87P13 21 days after 2nd dose N=69
Študija V87P13 21. dan po 2. odmerku n = 69
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL FOR SYRINGE AND 1-DOSE VIAL
OVOJNINAH OZNAKA ZA BRIZGO IN VIALO Z ENIM ODMERKOM
Foclivia suspension for injection Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Foclivia suspenzija za injiciranje cepivo proti pandemični gripi (H5N1) (površinski antigen, inaktiviran, z adjuvansom)
Study V87P1 21 days after 2nd dose N=37
Študija V87P1 21. dan po 2. odmerku n = 37
Study V87P13 21 days after 2nd dose N=197
Študija V87P13 21. dan po 2. odmerku n = 197
Study V87P13 21 days after 2nd dose N=210
Študija V87P13 21. dan po 2. odmerku n = 210
Study V87P1 21 days after 2nd dose N=149
Študija V87P1 21. dan po 2. odmerku n = 149
Foclivia suspension for injection Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted)
Foclivia suspenzija za injiciranje cepivo proti pandemični gripi (površinski antigeni, inaktivirani, z adjuvansom)
Study V87P13 21 days after 2nd dose N=207
Študija V87P13 21. dan po 2. odmerku n = 207
General disorders and administration site conditions Asthenia.
Splošne težave in spremembe na mestu aplikacije astenija
Study V87P13 21 days after 2nd dose N=143
Študija V87P13 21. dan po 2. odmerku n = 143
Foclivia suspension for injection in pre-filled syringe Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted)
Foclivia suspenzija za injiciranje v napolnjeni injekcijski brizgi cepivo proti pandemični gripi (površinski antigeni, inaktivirani, z adjuvansom)
A clinical trial (study V87P6) was conducted with a H5N1 vaccine combined with MF59C.1 adjuvant in 471 children from 6 months to 17 years of age.
Neželeni učinki iz kliničnih preskušanj pri otrocih, starih od 6 mesecev do 17 let V kliničnem preskušanju (študija V87P6) so primerjali cepivo H5N1, kombinirano z adjuvansom
Foclivia suspension for injection in multidose container Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Foclivia suspenzija za injiciranje v vsebniku z več odmerki cepivo proti pandemični gripi (H5N1) (površinski antigen, inaktiviran, z adjuvansom)
Foclivia suspension for injection in pre-filled syringe Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Foclivia suspenzija za injiciranje v napolnjeni injekcijski brizgi cepivo proti pandemični gripi (H5N1) (površinski antigen, inaktiviran, z adjuvansom)
Single dose vial: 1 vial containing a single dose (0.5 ml) for injection Instructions for administration of the vaccine:
Viala z enkratnim odmerkom: 1 viala, ki vsebuje enkratni odmerek (0,5 ml) za injiciranje.
Gastrointestinal disorders Gastrointestinal disorders such as nausea, vomiting, abdominal pain and diarrhoea.
angioedem Bolezni prebavil prebavne bolezni, vključno z navzeo, bruhanjem, trebušne bolečine in driska Bolezni živčevja glavobol, omotica, somnolenca, sinkopa.
Foclivia contains Thiomersal as a preservative and it is possible that you may experience an allergic reaction.
Zdravilo Foclivia vsebuje tiomersal kot konzervans.
The other ingredients are: thiomersal, sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate and water for injections.
Pomožne snovi so tiomersal, natrijev klorid, kalijev klorid, kalijev dihidrogen fosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat in voda za injekcije.
Sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, thiomersal, water for injections.
Natrijev klorid, kalijev klorid, kalijev dihidrogenfosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat, tiomersal, voda za injekcije.
Sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, water for injections.
Natrijev klorid, kalijev klorid, kalijev dihidrogenfosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat, voda za injekcije.
Name and address of the manufacturer responsible for batch release Seqirus Vaccines Ltd
Ime in naslov izdelovalca, odgovornega za sproščanje serije
Foclivia injection
suspenzija za injiciranje Viala
The other ingredients are: sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate and water for injections.
Pomožne snovi so natrijev klorid, kalijev klorid, kalijev dihidrogen fosfat, natrijev hidrogenfosfat dihidrat, magnezijev klorid heksahidrat, kalcijev klorid dihidrat in voda za injekcije.
You should discuss with your doctor whether you should receive FOCLIVIA The vaccine may be used during lactation.
O cepljenju z zdravilom Foclivia se posvetujte z zdravnikom.
AESIs will be defined as follows:
single radial haemolysis), so bili, kot sledi:
List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI, ZDRAVILA, POTI UPORABE, IMETNIKOV DOVOLJENJ ZA PROMET V DRŽAVAH ČLANICAH
2719 EE Zoetermeer The Netherlands
2719 EE Zoetermeer Nizozemska
AstraZeneca Kft. 1113 Budapest, Bocskai út 134-146 Hungary
Madžarska AstraZeneca Kft. 1113 Budapest, Bocskai út 134-146 Madžarska
Netherlands AstraZeneca BV Louis Pasteurlaan 5
Nizozemska AstraZeneca BV Louis Pasteurlaan 5
DK-2620 Albertslund, Denmark
DK-2620 Albertslund, Danska
AstraZeneca AS Boks 200 Vinderen NO-0319 Oslo, Norway
Norveška AstraZeneca AS Boks 200 Vinderen NO-0319 Oslo,
AstraZeneca SA Theotokopoulou 4 & Astronafton 151 25 Maroussi Greece
Theotokopoulou 4 & Astronafton 151 25 Maroussi Grčija
Almirall S.A., Ronda General Mitre, 151 08022 Barcelona, Spain
Ronda General Mitre, 151 08022 Barcelona, Španija
AstraZeneca GmbH 22876 Wedel, Germany
AstraZeneca GmbH 22876 Wedel, Nemčija
AstraZeneca SpA Palazzo Volta-via F Sforza - 20080 Basiglio (MI)Italy
Palazzo Volta-via F Sforza - 20080 Basiglio (MI) - Italija
AstraZeneca 1, Place Renault 92844 RueilMalmaison Cedex France
1, Place Renault 92844 Rueil-Malmaison Cedex Francija
AstraZeneca A/S Roskildevej 22, DK2620 Albertslund, Denmark
AstraZeneca A/S Roskildevej 22, DK-2620 Albertslund, Danska
Czech Republic AstraZeneca UK Ltd., Macclesfield, Cheshire, United Kingdom
AstraZeneca UK Ltd., Macclesfield, Cheshire,
WC2B 4AE, United Kingdom
London,WC2B 4AE, Velika Britanija
Capability Green, Luton, LU1 3LU, United Kingdom
AstraZeneca UK Limited, 600 Capability Green, Luton, LU1 3LU, Velika Britanija
Viktoriaallee 3-5, 52066 Aachen, Germany
Takeda Pharma GmbH, Viktoriaallee 3-5, 52066 Aachen, Nemčija
Laboratoires Takeda, 11-15, quai de Dion Bouton,
Laboratoires Takeda, 11-15, quai de Dion Bouton, 92816 Puteaux Cedex, Francija
AstraZeneca UK Limited
Slovenija AstraZeneca UK Limited 15 Stanhope Gate
LusomedicamentaSociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo 2730-055 Barcarena, Portugal
Portugalska Lusomedicamenta - Sociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo
28033 Madrid, Spain
2730-097 Barcarena, Portugalska
AstraZeneca AB 151 85 Södertälje, Sweden
AstraZeneca AB 151 85 Södertälje, Švedska
B-1180 Brussels
NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussels Belgija
AstraZeneca AB, S151 85 Södertälje, Sweden
AstraZeneca AB, S-151 85 Södertälje, Švedska
AstraZeneca AB, Strängnäsvägen 44, S-151 85 Södertälje, Sweden
AstraZeneca AB, S-151 85 Södertälje, švedska
Hytacand 16 mg 16 mg / 12.5 mg
Atacand Plus 16 mg/12.5 mg 16 mg / 12.5 mg
The European Commission granted a marketing authorisation valid throughout the European Union for Hexyon on 17 April 2013.
Evropska komisija je dovoljenje za promet z zdravilom Hexyon, veljavno po vsej Evropski uniji, izdala 17. aprila 2013.
What measures are being taken to ensure the safe and effective use of Hexyon?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Hexyon?
Other information about Hexyon
Druge informacije o zdravilu Hexyon
The full EPAR for Hexyon can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Hexyon je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Vaccination with Hexyon should be carried out according to official recommendations.
Cepljenje s cepivom Hexyon je treba izvajati v skladu z uradnimi priporočili.
This is a summary of the European public assessment report (EPAR) for Hexyon.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Hexyon.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Hexyon's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Hexyon večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Hexyon is a vaccine.
Zdravilo Hexyon je cepivo.
The effects were compared with a combination of separate vaccines designed to protect against the diseases included in Hexyon.
Učinke so primerjali s kombinacijo ločenih cepiv, namenjenih za zaščito pred boleznimi, ki so vključene v cepivo Hexyon.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Hexyon have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo cepiva, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Hexyon contains small amounts of materials derived from the bacteria and viruses it protects against.
Zdravilo Hexyon vsebuje majhne količine materiala, pridobljenega iz bakterij in virusov, proti katerim ščiti.
Regarding safety, the CHMP considered that Hexyon's overall safety profile is similar to other vaccines, although vaccination with Hexyon is more likely than similar vaccines to cause reactions (mainly at the injection site).
Kar zadeva varnost, je CHMP mnenja, da je celotni varnostni profil cepiva Hexyon podoben drugim cepivom, čeprav je bolj verjetno, da bo cepivo Hexyon povzročilo reakcije (večinoma na mestu injiciranja), kot druga cepiva.
It must not be used in children who have an uncontrolled or severe illness affecting the brain or nervous system, such as uncontrolled epilepsy, unless the condition has stabilised with treatment and the benefit clearly outweighs the risk.
Ne sme se uporabljati pri otrocih, ki imajo nenadzorovana ali resna obolenja možganov ali živčnega sistema, kot je nenadzorovana epilepsija (napadi), razen če se je stanje z zdravljenjem ustalilo in so koristi cepljenja veliko večje od tveganj.
What are the risks associated with Hexyon?
Kakšna tveganja so povezana z zdravilom Hexyon?
What benefits of Hexyon have been shown in studies?
Kakšne koristi je zdravilo Hexyon izkazalo v študijah?
Why is Hexyon approved?
Zakaj je bilo zdravilo Hexyon odobreno?
For more information about treatment with Hexyon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Hexyon preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Hexyon and what is it used for?
Kaj je zdravilo Hexyon in za kaj se uporablja?
Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local vaccination schedules.
Cepivo Hexyon je bilo proučevano v različnih državah sveta v 12 glavnih študijah, ki so vključevale več kot 3 400 otrok, starih od šest tednov do dveh let, in ki so v skladu z različnimi lokalnimi shemami cepljenja prejeli tri odmerke cepiva v prvih šestih mesecih življenja.
It is not intended to provide practical advice on how to use Hexyon.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Hexyon must not be used in children who have ever had an allergic reaction to Hexyon or a vaccine containing the same components, including substances used during the manufacture of the vaccine and which may be found at extremely low levels (such as the antibiotics neomycin or streptomycin).
Cepiva Hexyon se ne sme uporabljati pri otrocih, ki so v preteklosti imeli alergijsko reakcijo nanj ali cepivo, ki vsebuje enake sestavine, vključno s snovmi, ki se uporabljajo med procesom izdelave cepiva in ki so lahko prisotne v zelo majhnih količinah (kot sta antibiotika neomicin ali streptomicin).
The most common side effects with Hexyon include pain and redness at the site of injection, irritability and crying.
Najpogostejši neželeni učinki cepiva Hexyon vključujejo bolečino in rdečico na mestu injiciranja, razdražljivost in jok.
For practical information about using Hexyon, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Hexyon naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Vaccination with Hexyon should be postponed if a child has a moderate to severe fever.
Cepljenje s cepivom Hexyon je treba odložiti, če ima otrok srednje ali zelo povišano telesno temperaturo.
Hexyon or an appropriate combination of other vaccines can be used for the booster dose.
Za poživitveni odmerek se lahko uporabi cepivo Hexyon ali ustrezna kombinacija drugih cepiv.
Hexyon is available as a suspension for injection in vials and prefilled syringes.
Cepivo Hexyon je na voljo kot suspenzija za injiciranje v vialah in napolnjenih injekcijskih brizgah.
For the full list of all side effects reported with Hexyon, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Hexyon, glejte navodilo za uporabo.
The studies showed that protective antibody levels against the various diseases developed in between 90 and 100% of children after the first three doses of Hexyon; protection was maintained or improved when a booster dose was given.
Študije so pokazale, da so se zaščitne ravni protiteles, ki ščitijo pred različnimi boleznimi, razvile pri 90 do 100 % otrok po prvih treh odmerkih cepiva Hexyon.
These studies showed that Hexyon produces similar antibody profiles over time to comparable vaccines, and that the vaccine can be given at the same time as Prevenar and Rotarix.
Te študije so pokazale, da so po določenem času profili protiteles, ustvarjeni s cepivom Hexyon, podobni tistim, ki jih ustvarijo primerjalna cepiva, in da se sme cepivo uporabljati sočasno s cepivoma Prevenar in Roatrix.
Hexyon is given by deep injection into a muscle, normally in the upper thigh or the shoulder.
Cepivo Hexyon se daje običajno z injekcijo globoko v stegensko ali ramensko mišico.
It must not be used in children who have ever had encephalopathy (a brain disease) of unknown cause within seven days of receiving a vaccine containing pertussis components in the past.
Cepivo Hexyon se ne sme uporabljati pri otrocih, ki so v preteklosti preboleli encefalopatijo (obolenje možganov) neznanega vzroka v sedmih dneh po prejemu cepiva, ki je vsebovalo komponente oslovskega kašlja.
How does Hexyon work?
Kako zdravilo Hexyon deluje?
Hexyon is a vaccine containing active substances derived from diphtheria, tetanus, pertussis and Haemophilus influenzae type b bacteria, the hepatitis B virus, and inactivated polioviruses.
Zdravilo Hexyon je cepivo, ki vsebuje zdravilne učinkovine, pridobljene iz bakterij davice, tetanusa, oslovskega kašlja in Haemophilus influenzae tipa b, virusa hepatitisa B in neaktiviranih poliovirusov.
The CHMP noted that Hexyon has been shown to produce protective antibody levels against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and H. influenzae type b infections in children between six weeks and two years of age regardless of ethnicity.
Ugotovil je, da je bilo dokazano, da cepivo Hexyon ustvari zaščitne ravni protiteles proti davici, tetanusu, oslovskemu kašlju, virusu hepatitisa B, otroški paralizi in okužbam, ki jih povzročajo bakterije H. influenzae tipa b pri otrocih, starih od šest mesecev do dveh let, ne glede na njihovo etnično pripadnost.
How is Hexyon used?
Kako se zdravilo Hexyon uporablja?
Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)
Hexyon konjugirano (adsorbirano) cepivo proti davici, tetanusu, oslovskemu kašlju (acelularno, komponentno), hepatitisu B (rDNK), otroški paralizi (inaktivirano) in bakteriji Haemophilus influenzae tipa b
A subsequent study involving 455 children looked at the longer-term persistence of protective antibodies up to 3 years after a booster dose with Hexyon, and another study in 1,336 children evaluated the response to different lots of the vaccine and what happened when it was given with vaccines for infections caused by the bacterium Streptococcus pneumoniae (Prevenar) and rotavirus (Rotarix).
V drugi študiji so pri 1 336 otrocih proučevali odziv na različne skupine cepiv in kaj se zgodi, če se cepivo daje sočasno s cepivi za okužbe, ki jih povzročata bakterija Streptococcus pneumoniae (Prevenar) in rotavirus (Rotarix).
In the study, children who either received Hexyon produced a similar antibody response to those who received a comparator vaccine (Infanrix hexa), when given as a two-dose schedule followed by a booster 6 months later.
Študija je pokazala, da so se pri otrocih, ki so prejeli cepivo Hexyon v dveh odmerkih, ki mu je čez šest mesecev sledil obnovitveni odmerek, ustvarile primerljive ravni protiteles, kot pri tistih, ki so prejeli primerjalno cepivo (Infanrix hexa).
Treatment is continued for as long as the disease is not getting worse.
Zdravljenje se nadaljuje, dokler se bolezen ne poslabša.
Further information on Lynparza can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lynparza.
Nadaljnje informacije za zdravilo Lynparza so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/lynparza.
What measures are being taken to ensure the safe and effective use of Lynparza?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Lynparza?
Furthermore, while tablets can be taken with food or between meals, the patient should take the capsules at least 1 hour after food and not eat for up to 2 hours afterwards.
Tablete se lahko jemljejo s hrano ali med obroki, kapsule pa mora bolnik vzeti vsaj eno uro po obroku in nato ne sme jesti še vsaj dve uri.
The European Medicines Agency therefore decided that Lynparza's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Lynparza večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Lynparza received a marketing authorisation valid throughout the EU on 16 December 2014.
Za zdravilo Lynparza je bilo 16. decembra 2014 izdano dovoljenje za promet, veljavno po vsej EU.
The side effects with Lynparza were mostly mild or moderate and were generally manageable.
Neželeni učinki zdravila Lynparza so bili v glavnem blagi ali zmerni in so bili na splošno obvladljivi.
The most common side effects with Lynparza (which may affect more than 1 in 10 people) are tiredness, nausea (feeling sick), vomiting, diarrhoea, dyspepsia (heartburn), cough, headache, dysgeusia (taste disturbances), decreased appetite, dizziness, upper abdominal pain (stomach ache), dyspnoea (difficulty breathing), anaemia (low red blood cell counts), leucopenia (low white blood cell counts), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and thrombocytopenia (low blood platelet counts).
Najpogostejši neželeni učinki zdravila Lynparza (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so utrujenost, navzeja (siljenje na bruhanje), bruhanje, driska, dispepsija (zgaga), kašelj, glavobol, disgevzija (motnja okušanja), zmanjšan tek, omotica, bolečine v zgornjem delu trebuha, dispneja (oteženo dihanje), anemija (nizka raven rdečih krvnih celic), levkopenija (nizka raven belih krvnih celic), nevtropenija (nizka raven nevtrofilcev, vrste belih krvnih celic, ki se borijo proti okužbam) in trombocitopenija (nizko število trombocitov).
Women must not breastfeed during treatment with Lynparza and for a month after stopping treatment.
Ženske med zdravljenjem z zdravilom Lynparza in še en mesec po koncu zdravljenja ne smejo dojiti.
As for all medicines, data on the use of Lynparza are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Lynparza stalno spremljajo.
Other information about Lynparza
Druge informacije o zdravilu Lynparza
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lynparza have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Lynparza upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
In advanced ovarian cancer, the doctor may stop treatment after 2 years if X-rays show no signs of the cancer.
Pri napredovalem raku jajčnikov lahko zdravnik po dveh letih preneha zdravljenje, če rentgenski posnetki ne kažejo znakov raka.
Lynparza is a cancer medicine used on its own for:
Lynparza je zdravilo za zdravljenje raka, ki se uporablja kot samostojno zdravilo za:
Lynparza is available as tablets (100 and 150 mg) and capsules (50 mg) which the patient takes twice a day.
Zdravilo Lynparza je na voljo v obliki tablet (100 in 150 mg) in kapsul (50 mg), ki jih bolnik jemlje dvakrat na dan. Odmerki v miligramih se pri tabletah in kapsulah razlikujejo.
The dose and the choice between capsules and tablets of Lynparza depends on what disease it is being used for.
Odmerek in izbira tablet ali kapsul zdravila Lynparza sta odvisna od bolezni, za katero se zdravilo uporablja.
Lynparza can increase the time these patients live without their disease getting worse.
Zdravilo Lynparza lahko podaljša čas preživetja teh bolnikov brez poslabšanja bolezni.
What benefits of Lynparza have been shown in studies?
Kakšne koristi zdravila Lynparza so se pokazale v študijah?
Side effects reported with Lynparza are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Lynparza, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.